Blog

Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL – MediaMedic

MediaMedic/LinkedIn

Dec 27, 2024, 17:27

Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL – MediaMedic

MediaMedic shared a post on LinkedIn:

“ASH 2024, Dr. Peihua Lu: Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL.

The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology.

Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

In this feature, Hematology Frontier invited Professor Lu to share insights into the study’s findings, the strategy for expanding CD7 CAR-T indications, and future research plans.

Dr. Peihua Lu: Our team has been dedicated to developing CD7 CAR-T therapy for hematologic malignancies for several years. To date, we have treated over 300 cases, accumulating extensive clinical experience.

Our initial focus was on refractory or relapsed T-ALL and T-LBL. Among 60 patients, we observed an extraordinary 95% CR rate, even for extramedullary disease. Long-term outcomes post-allo-HSCT were equally impressive.

Expanding indications:

Acute myeloid leukemia (AML): Preliminary trials of CD7 CAR-T in CD7-positive AML showed a 70% CR rate, with results soon to be published in Blood.

New applications:

R/R PTCL: This Phase I trial, though limited in sample size, achieved 3 CRs among 5 patients, many with diffuse extramedullary disease—a remarkable outcome given the challenges of this malignancy.

Given the heterogeneity of T-cell hematologic malignancies, standalone CAR-T therapy is insufficient. Consolidative allo-HSCT remains crucial for sustained remission and potential cure. The future of CD7 CAR-T therapy is promising, and we will continue to refine its use to benefit more patients.”

Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL - MediaMedic

More posts featuring MediaMedic.

Dr. Peihua Lu is the Executive Medical Director of Lu Daopei Hospital and President of Beijing Lu Daopei Hematology Hospital.

She serves as a Committee Member of the Oncology Department at Capital Medical University, Chair of the Hematology Committee for the Chinese Non-Public Medical Institutions Association, and Member of the CSCO Leukemia Alliance Expert Committee.

She is also a Founding Member of the Non-Public Medical Institutions Association in China. In 2021, Dr. Lu received the Taishan Value Medical Award for Medical Management for her leadership and contributions to leukemia care and medical advancements.